ArticleCancer immunology research2019

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Hayley S Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.